How to diagnose why a life sciences product is declining and make the revitalize vs. exit call with evidence, not instinct.
The Goddess Who Governed the Hinge
Cardea was not a famous goddess. She did not command armies or shape fate. The Romans gave her a precise, unglamorous assignment: she governed door hinges. Specifically, she held power over the mechanism that made turning possible. Cardea could open what was shut and close what stood open. Her domain was not the decision to enter or leave. It was the pivot itself.
Roman households invoked Cardea not when they were building new doors but when existing ones had stopped working. A door that should open resisted. Cardea's intervention was diagnostic before it was corrective. You had to understand why the hinge had failed before you could fix it. Applying force without that diagnosis did not open the door. It stripped the mechanism entirely.
Product Managers (PMs) working a declining portfolio face Cardea's challenge every quarter. A western blot imaging system losing share, a qPCR master mix with shrinking reorders, a flow cytometry panel that once anchored a platform now sitting orphaned in the catalog. The instinct is to reach for force: a price cut, a refresh, a final push from the sales team. Cardea's lesson is older and more demanding. Diagnose the hinge before you turn it. The reason a product is declining determines whether you revitalize it or exit it. Revenue trajectory tells you nothing about the cause.
The Wrong Diagnostic Is Running
Most revitalize vs. exit debates start in the wrong place. A product appears in a portfolio review with a declining revenue line, and the conversation immediately moves to: how much would a refresh cost, and what would three-year upside look like? That is a financial model pretending to be a diagnosis.
Revenue decline is a symptom. It does not reveal whether the market has moved on, whether commercial execution has quietly broken down, or whether the product has lost its positioning anchor. Those three scenarios look identical in the quarterly numbers. They require completely different responses. A PM who treats them as interchangeable will either fund a revitalization with no commercial mechanism to recover, or exit a product that needed a territory reset and a fresh application note, not a product funeral.
The failure is not always visible in hindsight either. A next-generation sequencing sample prep kit that held strong gross margins but had lost its workflow anchor in pharma discovery accounts received a full formulation redesign. The science improved. The commercial problem did not. And a multiplex ELISA platform with genuine market obsolescence received two more years of conference presence before the portfolio team acknowledged that the upstream assay format its customers depended on had been replaced by bead-based alternatives. In both cases the diagnostic was wrong. Cardea's hinge was stripped before anyone understood why it had stopped turning.
Three Types of Decline, Three Different Responses
Before you build a revitalization business case or schedule a product exit, identify the decline type. There are three distinct causes, and they do not overlap.
-
Market-driven decline happens when the application or workflow your product serves has shifted at the field level. Your best accounts are still ordering, but their next-generation programs are specifying different technology. Competitors share the same downward trend. No commercial intervention reverses this. The signal is symmetric decline across all geographies and channels. The right response is exit with a migration path, not investment in a refresh.
-
Execution-driven decline is the most commonly misdiagnosed type because it appears in the revenue line as a product problem when it is a commercial motion failure. A chromatography resin losing share in one region while holding flat across others is not a product in decline. It is a territory, pricing, or application support gap. The signal is concentrated decline in specific channels or geographies while competitors are not experiencing the same trend. A reformulation solves the wrong problem. A commercial reset solves the right one.
-
Positioning-driven decline is the quietest type. The product still ships. Loyal accounts reorder out of habit. But ask your commercial team what specific problem this product solves that nothing else in your portfolio addresses, and watch them hesitate. The product has become an orphan, absorbed into a broader workflow without a defensible use case anchor. The signal is stable but shrinking revenue concentrated in a narrow customer base that cannot articulate why they buy. For instrument portfolios, this often surfaces differently: a healthy installed base with no new account pipeline, because nobody can articulate which new workflow the instrument is best suited for. The right response is repositioning around a specific, defensible application, or retiring the brand and absorbing the product into the platform where it now belongs.
Four Signals That Separate Revitalization from Sunset
Once you have identified the decline type, apply four diagnostic signals to determine whether revitalization is genuinely viable. These are not metrics to track over time. They are questions to answer once, clearly, before you commit to either path.
- Are your best accounts ordering less, or have they stopped ordering entirely? Volume decline and customer exit are different problems. A 30% volume reduction across your top accounts, where all are still ordering, signals a commercial or positioning issue. Six of your top ten accounts with no order in two quarters signals those customers have already moved on. You are watching the tail, not the turning point.
- Is your customer feedback showing frustration or indifference? Frustrated customers are still engaged. They file support tickets, push back on price increases, and ask when the next version is coming. Indifferent customers have already arranged alternatives and are ordering from residual habit. A structured call with five of your most loyal accounts answers this quickly. A needs list means revitalization potential. Polite non-answers about future plans mean the product has already been replaced in their planning.
- Does the product carry a technical claim no competitor can match? Assay sensitivity at a threshold competing kits do not reach, instrument throughput at a cycle time nobody else has published, antibody specificity validated across a broad tissue panel. A unique, defensible technical claim is the load-bearing element of any revitalization business case. Without one, you are investing in a product customers will always be able to substitute.
- Is the decline symmetric or concentrated? Map revenue by channel and geography for the last eight quarters. Symmetric decline points to a market-level shift. Concentrated decline points to a commercial or positioning failure. This single analysis frames every other conversation that follows.
The Revitalization Business Case
If the signals point toward revitalization, you need a business case built for scrutiny. This is not a revenue forecast with assumptions attached. A strong revitalization business case rests on three specific elements that together answer the question a skeptical portfolio review will ask: why did this happen, what exactly will you do about it, and how will you know if it worked? A business case built on revenue projection without a causal hypothesis will not survive a portfolio review with a CFO in the room.
A specific hypothesis for why the product declined. Not market softness. Not increased competition. Those are descriptions. A hypothesis names the mechanism: the product is declining because its buffer formulation is incompatible with the automated liquid handling platforms that the majority of target accounts now use as standard, and commercial support for the application note addressing this gap was deprioritized 18 months ago. That is testable. It names a cause and implies a specific intervention.
The minimum viable commercial intervention with a cost and a timeline. What is the smallest investment that tests whether the hypothesis is correct? For execution-driven decline, a territory pilot with a dedicated rep and a refreshed application note. For positioning-driven decline, a repositioning campaign targeting a specific application segment with updated collateral and a customer advisory input session. Size the intervention to the hypothesis, not to the maximum budget available.
A defined review window with a specific go/no-go signal. The timeline depends on the product and the intervention: instrument programs need longer runways than reagent campaigns. What matters is that you define the specific metric before the investment is approved. Not revenue improvement. The precise signal: reorder rate from target accounts increases by a defined threshold, net new accounts in the target segment reaches a specific number, or pipeline velocity from the repositioned application area moves within a measurable range. If you cannot define the go/no-go signal before you start, you do not have a revitalization plan. You have a delay tactic with a budget line.
Diagnose the Hinge. Then Turn It.
Cardea did not reward force. She rewarded precision. The household that applied force to a failing hinge stripped the mechanism and ended up with a door that could not be opened or closed reliably again. The PM who reaches for a price cut or a final sales push before diagnosing the type of decline does the same.
Identify the decline type. Run the four diagnostic signals. Build the revitalization business case around a hypothesis, a minimum viable intervention, and a defined go/no-go signal. Or, if the signals point to exit, execute the transition with the same precision: a migration path for your best accounts, a clear communication calendar, and resources released to the platform that is replacing you.
Diagnose the hinge. Then turn it. In the right direction.
Q: How do I get cross-functional agreement on which decline type we are dealing with? ▼
The PM who presents the symmetry analysis first controls the diagnostic framing. Pull the revenue breakdown by territory and customer type for the last eight quarters and put it in front of the group before anyone states a position. If the decline is symmetric across all segments, market-driven is hard to argue against. If it is concentrated, a commercial or positioning cause becomes the working hypothesis. The data frames the conversation and removes the room for function-specific blame that derails most portfolio reviews.
Without that anchor, every function defaults to protecting its own territory. R&D will argue market-driven to free up bandwidth. Sales and marketing will point at each other or at the product. Lead with the data, not the debate.
Q: What if the four signals point in different directions? ▼
Mixed signals usually mean the product is in transition between decline types rather than in a single stable failure mode. A product with frustrated customers but symmetric geographic decline is likely in the early stage of a market shift the organization has not yet accepted.
Weight the geographic symmetry analysis most heavily. Customer frustration reflects current value. Geographic symmetry reflects market direction. A loyal, frustrated customer base sitting on a symmetric decline curve is one where customers are right about the product today and wrong about where the market is going. The right response is an accelerated migration path that honors the current relationship while redirecting commercial energy toward the replacement platform.
Q: How do I handle a team that already has a strong opinion before I have run the diagnosis?▼
Do not argue with the opinion. Convert it into a hypothesis. Ask the person holding the view to name the specific mechanism driving decline, the intervention that would address it, and the metric that would confirm the hypothesis within a defined review window. Most strong opinions cannot survive that structure. If they can, you have a testable business case. If they cannot, the gap in the diagnosis becomes visible to everyone in the room, not just to you.
The hypothesis framework is not a bureaucratic obstacle. It is the fastest path to either validating a good instinct or surfacing a weak one, without the conversation becoming personal.
